Clinical trials: Cholangiocarcinomas
Hilar Cholangiocarcinoma
Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common hepatic malignancy after hepatocellular carcinoma (HCC).
- Trial name
- NCT02108145
- Testing
- bilateral metal stent insertion, unilateral metal stent insertion
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Air Force Military Medical University, China
Bile Duct Cancer, Gall Bladder Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous…
- Conditions
- Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05000294
- Testing
- Atezolizumab, Tivozanib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Unresectable Cholangiocarcinoma, Biliary Obstruction
Photodynamic Therapy (PDT) Cholangiocarcinoma Registry
Currently, very few centers offer Photodynamic therapy for unresectable Cholangiocarcinoma in the United States. Several European studies have reported the efficacy and safety of Photodynamic Therapy (PDT) for Cholangiocarcinoma…
- Conditions
- Unresectable Cholangiocarcinoma, Biliary Obstruction, Stent Obstruction, Biliary Stricture
- Trial name
- PDTRegistry (NCT01524146)
- Testing
- Photodynamic Therapy
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Biliary Tract Cancer, Biliary Tract Neoplasms
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working.
- Conditions
- Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT07146646
- Testing
- Trifluridine/tipiracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Case Comprehensive Cancer Center
Cholangiocarcinoma
Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma
This research is a prospective randomized controlled trial.It aimed to determine longterm outcomes and factors associated with increased survival after photodynamic therapy (PDT) through T-tube compared with biliary drainage…
- Trial name
- NCT01859169
- Testing
- Photodynamic therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- li xiong
Cholangiocarcinoma, Hilar
Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study
Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment.
- Trial name
- NCT07311798
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 300 people
- Sponsor
- Yongjun Chen
Cholangiocarcinoma, Gallbladder Cancer
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, GB cancer, and pancreatic cancer. In biliary stricture by malignancy, biliary drainage with placement of self-expanding metal stent…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, HCC
- Trial name
- NCT02659852
- Testing
- side by side, stent in stent
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Yonsei University
Liver Cancer, Hepatocellular Carcinoma
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
This study aims to develop a comprehensive artificial intelligence model system integrating preoperative multimodal data (CT/MRI imaging, clinical laboratory data, and radiology report text) to achieve two core objectives.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
- Trial name
- AIM-LCAP (NCT07658586)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangxi Medical University
Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
This is a prospective, open-label, single-arm phase II study designed to evaluate the efficacy and safety of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in combination with donafenib and pucotenlimab as first-line…
- Trial name
- NCT07353827
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Cholangiocarcinoma
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Background Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
- Trial name
- FAPIChol (NCT06355427)
- Testing
- [18F]F-FAPI PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Mara Veenstra, MD
Liver Neoplasm Malignant Primary, Cholangiocarcinoma
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
The investigators design a phase IIB clinical study to explore the efficacy and safety of lenvatinib plus pembrolizumab as a second-line treatment in patients with advanced hepatobiliary malignant tumors and to analyze potential…
- Conditions
- Liver Neoplasm Malignant Primary, Cholangiocarcinoma, Combinational Immunotherapy, Biomarker
- Trial name
- NCT03895970
- Testing
- Lenvatinib plus Pembrolizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Intrahepatic Cholangiocarcinoma
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial.
- Trial name
- LND for ICC (NCT03796819)
- Testing
- lymphadenectomy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Perihilar Cholangiocarcinoma
Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma
This prospective clinical trial aims to assess the feasibility, efficacy, and safety of a personalized radiofrequency ablation protocol coupled with complete biliary drainage for patients presenting with inoperable perihilar…
- Trial name
- COMBO-RFA (NCT05563870)
- Testing
- Endoluminal radiofrequency ablation, Endoscopic biliary stenting
- Where
- Romania
- Volunteers
- 26 people
- Sponsor
- Clinical Hospital Colentina
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Cholangiocarcinoma, Gallbladder Cancer
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- BOLSTER (NCT05712356)
- Testing
- certepetide, Durvalumab, Cisplatin
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- Lisata Therapeutics, Inc.
Biliary Tract Neoplasms, Cholangiocarcinoma
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
The objective of this study is to establish the recommended dose of selumetinib, a novel MEK inhibitor for use in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Neoplasms
- Trial name
- ABC-04 (NCT01242605)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- University College, London
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Overall Survival, Disease-free Survival
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking.
- Trial name
- MALRIC (NCT06462742)
- Testing
- Microwave ablation (MWA) versus Liver Resection (LR)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.